Compare Gigacloud Technology Inc (GCT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gigacloud Technology Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Gigacloud Technology Inc trades at $56.77 (market cap $2.02B), while State Street SPDR S&P Biotech ETF trades at $154.12 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 5× Gigacloud Technology Inc's market cap, and Gigacloud Technology Inc is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gigacloud Technology Inc for 21 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| GCT | XBI | |
|---|---|---|
Market Cap | $2.02B | $10.11B |
Volume | 1,020,985 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $56.42 | $169.55 |
52-Week Low | $25.46 | $104.99 |
Typical Hold Time | 21 Days | 37 Days |
Enterprise Value | $2.14B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GigaCloud Technology (GCT) trades at $55.65, down 0.55% on the day, with a bullish technical outlook from moving averages and a consensus analyst rating of Buy. The stock shows strong fundamentals with a P/E of 13.44, net income margin of 10.65%, and consistent earnings beats in recent quarters. Revenue is projected to grow from $1.29B in 2025 to $1.5B in 2026, while operating cash flow remains robust at $190.66M.
The investment outlook is positive given valuation attractiveness and earnings momentum, but risks include insider selling and reliance on international expansion. Analyst price targets suggest potential upside to $32.50 consensus, though the current price exceeds this, indicating mixed signals. Key catalysts are EU market growth and continued execution against guidance.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
